-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Cell-culture-derived -X- _ O
( -X- _ O
CC -X- _ O
) -X- _ O
influenza -X- _ O
vaccine -X- _ O
production -X- _ O
methods -X- _ O
could -X- _ O
provide -X- _ O
benefits -X- _ O
over -X- _ O
classical -X- _ O
embryonated-egg -X- _ O
technology -X- _ O
, -X- _ O
including -X- _ O
a -X- _ O
higher -X- _ O
production -X- _ O
capacity -X- _ O
and -X- _ O
the -X- _ O
faster -X- _ O
creation -X- _ O
of -X- _ O
a -X- _ O
supply -X- _ O
that -X- _ O
meets -X- _ O
demand. -X- _ O
METHODS -X- _ O
: -X- _ O
A -X- _ O
CC-inactivated -X- _ B-Intervention
split-virus -X- _ I-Intervention
influenza -X- _ I-Intervention
A -X- _ I-Intervention
/ -X- _ I-Intervention
Indonesia -X- _ I-Intervention
/ -X- _ I-Intervention
5 -X- _ I-Intervention
/ -X- _ I-Intervention
2005 -X- _ I-Intervention
( -X- _ I-Intervention
H5N1 -X- _ I-Intervention
) -X- _ I-Intervention
vaccine -X- _ I-Intervention
derived -X- _ I-Intervention
from -X- _ I-Intervention
the -X- _ I-Intervention
EB66 -X- _ I-Intervention
cell -X- _ I-Intervention
line -X- _ I-Intervention
( -X- _ I-Intervention
hereafter -X- _ I-Intervention
, -X- _ I-Intervention
“CC-H5N1” -X- _ I-Intervention
) -X- _ I-Intervention
was -X- _ O
investigated -X- _ O
in -X- _ O
a -X- _ O
phase -X- _ O
1 -X- _ O
randomized -X- _ O
, -X- _ O
blinded -X- _ O
study. -X- _ O
Healthy -X- _ B-Patient
adults -X- _ I-Patient
( -X- _ I-Patient
n -X- _ I-Patient
= -X- _ I-Patient
521 -X- _ I-Patient
) -X- _ I-Patient
received -X- _ O
2 -X- _ B-Intervention
vaccine -X- _ I-Intervention
doses -X- _ I-Intervention
( -X- _ I-Intervention
days -X- _ I-Intervention
0 -X- _ I-Intervention
and -X- _ I-Intervention
21 -X- _ I-Intervention
) -X- _ I-Intervention
of -X- _ I-Intervention
either -X- _ I-Intervention
investigational -X- _ I-Intervention
CC-H5N1 -X- _ I-Intervention
vaccine -X- _ I-Intervention
( -X- _ I-Intervention
1.9 -X- _ I-Intervention
µg -X- _ I-Intervention
or -X- _ I-Intervention
3.75 -X- _ I-Intervention
µg -X- _ I-Intervention
of -X- _ I-Intervention
hemagglutinin -X- _ I-Intervention
antigen -X- _ I-Intervention
[ -X- _ I-Intervention
HA -X- _ I-Intervention
] -X- _ I-Intervention
with -X- _ I-Intervention
the -X- _ I-Intervention
AS03 -X- _ I-Intervention
adjuvant -X- _ I-Intervention
system -X- _ I-Intervention
or -X- _ I-Intervention
15 -X- _ I-Intervention
µg -X- _ I-Intervention
of -X- _ I-Intervention
plain -X- _ I-Intervention
HA -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ I-Intervention
embryonated-egg-derived -X- _ I-Intervention
vaccines -X- _ I-Intervention
( -X- _ I-Intervention
3.75 -X- _ I-Intervention
µg -X- _ I-Intervention
of -X- _ I-Intervention
HA -X- _ I-Intervention
with -X- _ I-Intervention
AS03 -X- _ I-Intervention
or -X- _ I-Intervention
15 -X- _ I-Intervention
µg -X- _ I-Intervention
of -X- _ I-Intervention
plain -X- _ I-Intervention
HA -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ O
or -X- _ O
placebo. -X- _ B-Comparison
Assessment -X- _ O
of -X- _ O
the -X- _ O
adjuvant -X- _ O
effect -X- _ O
and -X- _ O
immunogenicity -X- _ O
was -X- _ O
performed -X- _ O
using -X- _ O
Center -X- _ O
for -X- _ O
Biologics -X- _ O
Evaluation -X- _ O
and -X- _ O
Research -X- _ O
acceptability -X- _ O
criteria -X- _ O
21 -X- _ O
days -X- _ O
after -X- _ O
dose -X- _ O
2. -X- _ O
Safety -X- _ O
was -X- _ O
assessed -X- _ O
until -X- _ O
month -X- _ O
12. -X- _ O
RESULTS -X- _ O
: -X- _ O
AS03-adjuvanted -X- _ O
CC-H5N1 -X- _ O
elicited -X- _ O
a -X- _ O
homologous -X- _ O
hemagglutination -X- _ O
inhibition -X- _ O
antibody -X- _ O
response -X- _ O
that -X- _ O
satisfied -X- _ O
immunogenicity -X- _ O
criteria -X- _ O
21 -X- _ O
days -X- _ O
after -X- _ O
dose -X- _ O
2 -X- _ O
and -X- _ O
persisted -X- _ O
at -X- _ O
month -X- _ O
12. -X- _ O
Adjuvant -X- _ O
effect -X- _ O
and -X- _ O
immune -X- _ O
response -X- _ O
against -X- _ O
a -X- _ O
drift-variant -X- _ O
strain -X- _ O
were -X- _ O
demonstrated. -X- _ O
No -X- _ O
vaccine-related -X- _ O
serious -X- _ O
adverse -X- _ O
events -X- _ O
were -X- _ O
reported. -X- _ O
The -X- _ O
immunogenicity -X- _ B-Outcome
and -X- _ I-Outcome
safety -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
CC-H5N1 -X- _ I-Outcome
formulation -X- _ I-Outcome
containing -X- _ I-Outcome
3.75 -X- _ I-Outcome
µg -X- _ I-Outcome
of -X- _ I-Outcome
HA -X- _ I-Outcome
and -X- _ I-Outcome
AS03 -X- _ I-Outcome
appeared -X- _ I-Outcome
to -X- _ I-Outcome
be -X- _ I-Outcome
similar -X- _ I-Outcome
to -X- _ I-Outcome
those -X- _ I-Outcome
for -X- _ I-Outcome
the -X- _ I-Outcome
licensed -X- _ I-Outcome
egg-derived -X- _ I-Outcome
AS03-adjuvanted -X- _ I-Outcome
control -X- _ I-Outcome
vaccine. -X- _ I-Outcome
CONCLUSIONS -X- _ O
: -X- _ O
The -X- _ O
feasibility -X- _ O
of -X- _ O
the -X- _ O
EB66 -X- _ O
cell -X- _ O
line -X- _ O
to -X- _ O
produce -X- _ O
an -X- _ O
immunogenic -X- _ O
influenza -X- _ O
vaccine -X- _ O
with -X- _ O
acceptable -X- _ O
safety -X- _ O
profile -X- _ O
was -X- _ O
demonstrated. -X- _ O
Antigen -X- _ O
sparing -X- _ O
was -X- _ O
achieved -X- _ O
through -X- _ O
combination -X- _ O
with -X- _ O
AS03 -X- _ O
adjuvant. -X- _ O
This -X- _ O
CC-H5N1 -X- _ O
might -X- _ O
contribute -X- _ O
to -X- _ O
the -X- _ O
rapid -X- _ O
access -X- _ O
of -X- _ O
vaccine -X- _ O
in -X- _ O
the -X- _ O
event -X- _ O
of -X- _ O
an -X- _ O
influenza -X- _ O
A -X- _ O
( -X- _ O
H5N1 -X- _ O
) -X- _ O
pandemic. -X- _ O
CLINICAL -X- _ O
TRIALS -X- _ O
REGISTRATION -X- _ O
: -X- _ O
NCT01236040 -X- _ O
. -X- _ O

